Abstract
Onset of many forms of epilepsy occurs after an initial epileptogenic insult or as a result of an identified genetic defect. Given that the precipitating insult is known, these epilepsies are, in principle, amenable to secondary prevention. However, development of preventive treatments is difficult because only a subset of individuals will develop epilepsy and we cannot currently predict which individuals are at the highest risk. Biomarkers that enable identification of these individuals would facilitate clinical trials of potential anti-epileptogenic treatments, but no such prognostic biomarkers currently exist. Several putative molecular, imaging, electroencephalographic and behavioural biomarkers of epileptogenesis have been identified, but clinical translation has been hampered by fragmented and poorly coordinated efforts, issues with inter-model reproducibility, study design and statistical approaches, and difficulties with validation in patients. These challenges demand a strategic roadmap to facilitate the identification, characterization and clinical validation of biomarkers for epileptogenesis. In this Review, we summarize the state of the art with respect to biomarker research in epileptogenesis and propose a five-phase roadmap, adapted from those developed for cancer and Alzheimer disease, that provides a conceptual structure for biomarker research.
Key points
-
Many forms of epilepsy manifest and/or are diagnosed months or even years after an epileptogenic insult or identification of a genetic defect.
-
Epilepsies that result from an insult or genetic defect could be amenable to secondary prevention but preventive treatments are not available.
-
Development of preventive therapies is complicated by the fact that only a subset of at-risk individuals develop clinical epilepsy.
-
Biomarkers are needed to clearly identify individuals who have the highest risk of developing epilepsy after an epileptogenic insult.
-
We propose a strategic roadmap designed to facilitate the identification, characterization and clinical validation of biomarkers for epileptogenesis.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
World Health Organization. Epilepsy. Epilepsy: Key Facts. https://www.who.int/news-room/fact-sheets/detail/epilepsy (2019).
Pitkanen, A. & Lukasiuk, K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol. 10, 173–186 (2011).
GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 56–87 (2019).
Simonato, M. et al. The challenge and promise of anti-epileptic therapy development in animal models. Lancet Neurol. 13, 949–960 (2014). This review highlights the need for biomarker identification to develop disease-modifying therapies of epilepsy.
Loscher, W. & Schmidt, D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 52, 657–678 (2011). This study shows that newer anti-epileptic drugs have provided limited improvements over the older ones.
Simonato, M. et al. Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia 53, 1860–1867 (2012).
Pitkanen, A. et al. Advances in the development of biomarkers for epilepsy. Lancet Neurol. 15, 843–856 (2016).
Pitkanen, A., Ekolle Ndode-Ekane, X., Lapinlampi, N. & Puhakka, N. Epilepsy biomarkers - toward etiology and pathology specificity. Neurobiol. Dis. 123, 42–58 (2019). This review presents a summary of potential biomarkers of epilepsy.
FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and Other Tools) Recommendations https://www.ncbi.nlm.nih.gov/books/NBK326791/ (2016). A reference resource for the definition and classification of biomarkers.
Meguid, N. et al. Altered S100 calcium-binding protein B and matrix metallopeptidase 9 as biomarkers of mesial temporal lobe epilepsy with hippocampus sclerosis. J. Mol. Neurosci. 66, 482–491 (2018).
Asadollahi, M. & Simani, L. The diagnostic value of serum UCHL-1 and S100-B levels in differentiate epileptic seizures from psychogenic attacks. Brain Res. 1704, 11–15 (2018).
Simani, L., Elmi, M. & Asadollahi, M. Serum GFAP level: a novel adjunctive diagnostic test in differentiate epileptic seizures from psychogenic attacks. Seizure 61, 41–44 (2018).
Huang, Q., Liu, J., Shi, Z. & Zhu, X. Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis. Cell Mol. Biol. 66, 39–47 (2020).
Nass, R. D., Wagner, M., Surges, R. & Holdenrieder, S. Time courses of HMGB1 and other inflammatory markers after generalized convulsive seizures. Epilepsy Res. 162, 106301 (2020).
Pauletti, A. et al. Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy. Brain 142, e39 (2019).
Alles, J. et al. An estimate of the total number of true human miRNAs. Nucleic Acids Res. 47, 3353–3364 (2019).
Toffolo, K. et al. Circulating microRNAs as biomarkers in traumatic brain injury. Neuropharmacology 145, 199–208 (2018).
Vijayan, M. & Reddy, P. H. Peripheral biomarkers of stroke: focus on circulatory microRNAs. Biochim. Biophys. Acta 1862, 1984–1993 (2016).
Dewdney, B. et al. Circulating microRNAs as biomarkers for acute ischemic stroke: a systematic review. J. Stroke Cerebrovasc. Dis. 27, 522–530 (2018).
Henshall, D. C. Manipulating microRNAs in murine models: targeting the multi-targeting in epilepsy. Epilepsy Curr. 17, 43–47 (2017).
Brennan, G. P. & Henshall, D. C. MicroRNAs as regulators of brain function and targets for treatment of epilepsy. Nat. Rev. Neurol. 16, 506–519 (2020).
Gorter, J. A. et al. Hippocampal subregion-specific microRNA expression during epileptogenesis in experimental temporal lobe epilepsy. Neurobiol. Dis. 62, 508–520 (2014).
Roncon, P. et al. MicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine-induced epilepsy – comparison with human epileptic samples. Sci. Rep. 5, 14143 (2015).
Brennan, G. P. et al. Genome-wide microRNA profiling of plasma from three different animal models identifies biomarkers of temporal lobe epilepsy. Neurobiol. Dis. 144, 105048 (2020).
Raoof, R. et al. Dual-center, dual-platform microRNA profiling identifies potential plasma biomarkers of adult temporal lobe epilepsy. EBioMedicine 38, 127–141 (2018).
Kamnaksh, A. et al. Harmonization of pipeline for preclinical multicenter plasma protein and miRNA biomarker discovery in a rat model of post-traumatic epileptogenesis. Epilepsy Res. 149, 92–101 (2019).
Iwuchukwu, I. et al. MicroRNA regulatory network as biomarkers of late seizure in patients with spontaneous intracerebral hemorrhage. Mol. Neurobiol. 57, 2346–2357 (2020).
Enright, N., Simonato, M. & Henshall, D. C. Discovery and validation of blood microRNAs as molecular biomarkers of epilepsy: ways to close current knowledge gaps. Epilepsia Open 3, 427–436 (2018).
Trelinska, J. et al. Abnormal serum microRNA profiles in tuberous sclerosis are normalized during treatment with everolimus: possible clinical implications. Orphanet J. Rare Dis. 11, 129 (2016).
Wang, X. et al. MicroRNA-134 plasma levels before and after treatment with valproic acid for epilepsy patients. Oncotarget 8, 72748–72754 (2017).
Redell, J. B., Moore, A. N., Ward, N. H. 3rd, Hergenroeder, G. W. & Dash, P. K. Human traumatic brain injury alters plasma microRNA levels. J. Neurotrauma 27, 2147–2156 (2010).
Mitra, B. et al. Plasma micro-RNA biomarkers for diagnosis and prognosis after traumatic brain injury: a pilot study. J. Clin. Neurosci. 38, 37–42 (2017).
Hogg, M. C. et al. Elevation in plasma tRNA fragments precede seizures in human epilepsy. J. Clin. Invest. 129, 2946–2951 (2019).
McArdle, H. et al. “TORNADO” - Theranostic One-Step RNA Detector; microfluidic disc for the direct detection of microRNA-134 in plasma and cerebrospinal fluid. Sci. Rep. 7, 1750 (2017).
Cheng, Y., Dong, L., Zhang, J., Zhao, Y. & Li, Z. Recent advances in microRNA detection. Analyst 143, 1758–1774 (2018).
Diamond, M. L. et al. IL-1β associations with posttraumatic epilepsy development: a genetics and biomarker cohort study. Epilepsia 55, 1109–1119 (2014).
Ding, K., Gupta, P. K. & Diaz-Arrastia, R. in Translational Research in Traumatic Brain Injury Ch. 14 (eds Laskowitz, D. & Grant, G.) (CRC Press/Taylor and Francis Group, 2016).
Pitkanen, A. & Immonen, R. Epilepsy related to traumatic brain injury. Neurotherapeutics 11, 286–296 (2014).
Salazar, A. M. & Grafman, J. Post-traumatic epilepsy: clinical clues to pathogenesis and paths to prevention. Handb. Clin. Neurol. 128, 525–538 (2015).
Agoston, D. V. & Kamnaksh, A. Protein biomarkers of epileptogenicity after traumatic brain injury. Neurobiol. Dis. 123, 59–68 (2018).
Lewis, D. V. et al. Hippocampal sclerosis after febrile status epilepticus: the FEBSTAT study. Ann. Neurol. 75, 178–185 (2014).
Huttunen, J. K. et al. Detection of hyperexcitability by functional magnetic resonance imaging after experimental traumatic brain injury. J. Neurotrauma 35, 2708–2717 (2018).
Vezzani, A., Pascente, R. & Ravizza, T. Biomarkers of epileptogenesis: the focus on glia and cognitive dysfunctions. Neurochem. Res. 42, 2089–2098 (2017).
Nicolo, J. P., O’Brien, T. J. & Kwan, P. Role of cerebral glutamate in post-stroke epileptogenesis. Neuroimage Clin. 24, 102069 (2019).
Shultz, S. R. et al. Can structural or functional changes following traumatic brain injury in the rat predict epileptic outcome? Epilepsia 54, 1240–1250 (2013).
Cleeren, E. et al. Positron emission tomography imaging of cerebral glucose metabolism and type 1 cannabinoid receptor availability during temporal lobe epileptogenesis in the amygdala kindling model in rhesus monkeys. Epilepsia 59, 959–970 (2018).
Toczek, M. T. et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 60, 749–756 (2003).
Guiard, B. P. & Di Giovanno, G. Central serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link? Front. Pharmacol. 6, 46 (2015).
Bascunana, P. et al. PET neuroimaging reveals serotonergic and metabolic dysfunctions in the hippocampal electrical kindling model of epileptogenesis. Neuroscience 409, 101–110 (2019).
Choi, H. et al. In vivo imaging of mGluR5 changes during epileptogenesis using [11C]ABP688 PET in pilocarpine-induced epilepsy rat model. PLoS ONE 9, e92765 (2014).
Celli, R. et al. Targeting metabotropic glutamate receptors in the treatment of epilepsy: rationale and current status. Expert Opin. Ther. Targets 23, 341–351 (2019).
Gershen, L. D. et al. Neuroinflammation in temporal lobe epilepsy measured using positron emission tomographic imaging of translocator protein. JAMA Neurol. 72, 882–888 (2015).
Dickstein, L. P. et al. Neuroinflammation in neocortical epilepsy measured by PET imaging of translocator protein. Epilepsia 60, 1248–1254 (2019).
Brackhan, M. et al. [(18)F]GE180 positron emission tomographic imaging indicates a potential double-hit insult in the intrahippocampal kainate mouse model of temporal lobe epilepsy. Epilepsia 59, 617–626 (2018).
Bertoglio, D. et al. Non-invasive PET imaging of brain inflammation at disease onset predicts spontaneous recurrent seizures and reflects comorbidities. Brain Behav. Immun. 61, 69–79 (2017).
Russmann, V. et al. Identification of brain regions predicting epileptogenesis by serial [(18)F]GE-180 positron emission tomography imaging of neuroinflammation in a rat model of temporal lobe epilepsy. Neuroimage Clin. 15, 35–44 (2017).
Bar-Klein, G. et al. Imaging blood-brain barrier dysfunction as a biomarker for epileptogenesis. Brain 140, 1692–1705 (2017).
Breuer, H. et al. Multimodality imaging of blood-brain barrier impairment during epileptogenesis. J. Cereb. Blood Flow. Metab. 37, 2049–2061 (2017).
Koepp, M. J. et al. Neuroinflammation imaging markers for epileptogenesis. Epilepsia 58, 11–19 (2017).
Singh, A. K. et al. Dynamic contrast-enhanced (DCE) MRI derived kinetic perfusion indices may help predicting seizure control in single calcified neurocysticercosis. Magn. Reson. Imaging 49, 55–62 (2018).
Immonen, R. et al. Harmonization of pipeline for preclinical multicenter MRI biomarker discovery in a rat model of post-traumatic epileptogenesis. Epilepsy Res. 150, 46–57 (2019).
Levine, D., McDonald, R. J. & Kressel, H. Y. Gadolinium retention after contrast-enhanced MRI. JAMA 320, 1853–1854 (2018).
Janeczko, K., Kosonowska, E., Kiepura, A., Weglarz, W. & Setkowicz, Z. Volumetric response of the adult brain to seizures depends on the developmental stage when systemic inflammation was induced. Epilepsy Behav. 78, 280–287 (2018).
Andrade, P., Nissinen, J. & Pitkanen, A. Generalized seizures after experimental traumatic brain injury occur at the transition from slow-wave to rapid eye movement sleep. J. Neurotrauma 34, 1482–1487 (2017).
Bragin, A. et al. Pathologic electrographic changes after experimental traumatic brain injury. Epilepsia 57, 735–745 (2016).
Milikovsky, D. Z. et al. Electrocorticographic dynamics as a novel biomarker in five models of epileptogenesis. J. Neurosci. 37, 4450–4461 (2017).
Bahari, F., Ssentongo, P., Schiff, S. J. & Gluckman, B. J. A brain-heart biomarker for epileptogenesis. J. Neurosci. 38, 8473–8483 (2018).
Perucca, P., Smith, G., Santana-Gomez, C., Bragin, A. & Staba, R. Electrophysiological biomarkers of epileptogenicity after traumatic brain injury. Neurobiol. Dis. 123, 69–74 (2019).
Zijlmans, M. et al. High-frequency oscillations as a new biomarker in epilepsy. Ann. Neurol. 71, 169–178 (2012).
Menendez de la Prida, L., Staba, R. J. & Dian, J. A. Conundrums of high-frequency oscillations (80-800 Hz) in the epileptic brain. J. Clin. Neurophysiol. 32, 207–219 (2015).
Worrell, G. A. et al. Recording and analysis techniques for high-frequency oscillations. Prog. Neurobiol. 98, 265–278 (2012).
Kim, J. A. et al. Epileptiform activity in traumatic brain injury predicts post-traumatic epilepsy. Ann. Neurol. 83, 858–862 (2018).
Tubi, M. A. et al. Early seizures and temporal lobe trauma predict post-traumatic epilepsy: A longitudinal study. Neurobiol. Dis. 123, 115–121 (2018).
Wu, J. Y. et al. Clinical electroencephalographic biomarker for impending epilepsy in asymptomatic tuberous sclerosis complex infants. Pediatr. Neurol. 54, 29–34 (2016).
Jain, S. V. et al. Prediction of neonatal seizures in hypoxic-ischemic encephalopathy using electroencephalograph power analyses. Pediatr. Neurol. 67, 64–70.e2 (2017).
Besio, W. G. et al. High-frequency oscillations recorded on the scalp of patients with epilepsy using tripolar concentric ring electrodes. IEEE J. Transl. Eng. Health Med. 2, 2000111 (2014).
Broer, S. & Loscher, W. Novel combinations of phenotypic biomarkers predict development of epilepsy in the lithium-pilocarpine model of temporal lobe epilepsy in rats. Epilepsy Behav. 53, 98–107 (2015).
Pascente, R. et al. Cognitive deficits and brain myo-inositol are early biomarkers of epileptogenesis in a rat model of epilepsy. Neurobiol. Dis. 93, 146–155 (2016).
Pepe, M. S. et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054–1061 (2001). A roadmap for identification of early biomarkers of cancer.
Frisoni, G. B. et al. Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. Lancet Neurol. 16, 661–676 (2017). A roadmap for identification of early biomarkers of Alzheimer disease.
Hampel, H. et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat. Rev. Neurol. 14, 639–652 (2018).
International League Against Epilepsy Consortium on Complex Epilepsies. Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nat. Commun. 9, 5269 (2018).
Oyrer, J. et al. Ion channels in genetic epilepsy: from genes and mechanisms to disease-targeted therapies. Pharmacol. Rev. 70, 142–173 (2018).
Pitkänen, A., Buckmaster, P., Galanopoulou, A. S. & Moshé, S. Models of Seizures and Epilepsy 2nd edn (Academic Press, 2017).
Sculier, C., Gainza-Lein, M., Sanchez Fernandez, I. & Loddenkemper, T. Long-term outcomes of status epilepticus: a critical assessment. Epilepsia 59, 155–169 (2018).
Pujar, S. & Scott, R. C. Long-term outcomes after childhood convulsive status epilepticus. Curr. Opin. Pediatr. 31, 763–768 (2019).
Levesque, M., Avoli, M. & Bernard, C. Animal models of temporal lobe epilepsy following systemic chemoconvulsant administration. J. Neurosci. Methods 260, 45–52 (2016).
Frey, L. C. Epidemiology of posttraumatic epilepsy: a critical review. Epilepsia 44, 11–17 (2003).
Xu, T. et al. Risk factors for posttraumatic epilepsy: a systematic review and meta-analysis. Epilepsy Behav. 67, 1–6 (2017).
Klein, P. & Tyrlikova, I. No prevention or cure of epilepsy as yet. Neuropharmacology 168, 107762 (2020).
Xiong, Y., Mahmood, A. & Chopp, M. Animal models of traumatic brain injury. Nat. Rev. Neurosci. 14, 128–142 (2013).
Camilo, O. & Goldstein, L. B. Seizures and epilepsy after ischemic stroke. Stroke 35, 1769–1775 (2004).
Feyissa, A. M., Hasan, T. F. & Meschia, J. F. Stroke-related epilepsy. Eur. J. Neurol. 26, 18–e13 (2019).
Sommer, C. J. Ischemic stroke: experimental models and reality. Acta Neuropathol. 133, 245–261 (2017).
Macrae, I. M. Preclinical stroke research–advantages and disadvantages of the most common rodent models of focal ischaemia. Br. J. Pharmacol. 164, 1062–1078 (2011).
Glass, H. C. et al. Risk factors for epilepsy in children with neonatal encephalopathy. Pediatr. Res. 70, 535–540 (2011).
Liu, X., Jary, S., Cowan, F. & Thoresen, M. Reduced infancy and childhood epilepsy following hypothermia-treated neonatal encephalopathy. Epilepsia 58, 1902–1911 (2017).
Hamdy, N., Eide, S., Sun, H. S. & Feng, Z. P. Animal models for neonatal brain injury induced by hypoxic ischemic conditions in rodents. Exp. Neurol. 334, 113457 (2020).
Ramantani, G. & Holthausen, H. Epilepsy after cerebral infection: review of the literature and the potential for surgery. Epileptic Disord. 19, 117–136 (2017).
Vezzani, A. et al. Infections, inflammation and epilepsy. Acta Neuropathol. 131, 211–234 (2016).
Pallud, J. et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 137, 449–462 (2014).
Kirschstein, T. & Kohling, R. Animal models of tumour-associated epilepsy. J. Neurosci. Methods 260, 109–117 (2016).
Geis, C., Planaguma, J., Carreno, M., Graus, F. & Dalmau, J. Autoimmune seizures and epilepsy. J. Clin. Invest. 129, 926–940 (2019).
Shen, C. H. et al. Seizures and risk of epilepsy in anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis. Ann. Clin. Transl. Neurol. 7, 1392–1399 (2020).
Taraschenko, O. et al. A mouse model of seizures in anti-N-methyl-D-aspartate receptor encephalitis. Epilepsia 60, 452–463 (2019).
Petit-Pedrol, M. et al. LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory. Brain 141, 3144–3159 (2018).
Choy, M. et al. A novel, noninvasive, predictive epilepsy biomarker with clinical potential. J. Neurosci. 34, 8672–8684 (2014).
Acknowledgements
The contents of this article are based on proposals made at a workshop organized by the National Institute of Neurological Disease and Stroke (NINDS) to accelerate therapies for anti-epileptogenesis and disease modification (Bethesda, MD, USA, 6th–8th August 2018). M.S. is supported in part by the European Community (FP7-HEALTH project 602102 [EPITARGET]). D.C.H. is supported by the Science Foundation Ireland (SFI) grant number 13/IA/1891 and 16/RC/3948 and co-funded under the European Regional Development Fund and by FutureNeuro industry partners. Other support to D.C.H. was from the European Union’s ‘Seventh Framework’ Programme (FP7) under Grant Agreement no. 602130 (EpimiRNA) and Medical Research Charities Group (2016-9). A.P. is supported by the Academy of Finland, European Community (FP7-HEALTH project 602102 [EPITARGET]), the National Institute of Neurological Disorders and Stroke (NINDS) Centers without Walls [grant number U54 NS100064]. W.H.T. is supported by the Division of Intramural Research, NINDS NIH. F.H.K. and K.K.W. are supported in part by a CURE grant received from the United States Army Medical Research and Materiel Command, Department of Defense (DoD), through the Psychological Health and Traumatic Brain Injury Research Program under award no. W81XWH-15-2-0069. K.S.W. is in part supported with Federal funds from the NINDS, National Institutes of Health, Department of Health and Human Services, under contract no. HHSN271201600048C.
Review criteria
We searched PubMed for articles published up to August 2020, including experimental and clinical studies published in English. Generic searches using free terms (such as “epilepsy” AND “biomarker”) had low specificity and retrieved a large number of articles (2,812 articles), the majority of which provided no clear evidence to support the notion that a particular molecular, imaging, electroencephalography (EEG) or behavioural alteration could be considered a biomarker of epilepsy or epileptogenesis. Use of medical subject heading (MeSH) terms (such as “Epilepsy”[Majr] AND “Biomarkers”[Majr]) had low sensitivity and retrieved few articles (149 articles). Similarly, unsatisfactory results were obtained when using the generic search “epileptogenesis” AND “biomarker” or “Biomarkers”[Majr] (339 and 45 articles, respectively). Therefore, we refined the generic search with specific biomarker types (molecular, imaging, EEG, behavioural) by adding one or more subtopic-specific additional query term. Eligible papers were then read and filtered on the basis of experimental methodology — studies that included a receiver operating characteristic (ROC) analysis or an equivalent methodology for ascertaining discriminative value were prioritized. In addition, articles from leaders in the field of epilepsy and epileptogenesis were included on the basis of the investigators’ expertise. Consequently, the final selection of biomarkers discussed in this Review comes from a narrative rather than a systematic search. For Table 1, rates and other information were compiled from reviews or, in some cases, original references identified by use of tailored search terms for each risk factor.
Author information
Authors and Affiliations
Contributions
The Review was envisioned and planned as a collaborative activity within the Biomarkers and Translational Science Working Group organized by the National Institute of Neurological Disease and Stroke within the initiative “Accelerating Therapies for Antiepileptogenesis and Disease Modification”. All authors contributed to the conception, design, literature search and writing for this Review.
Corresponding author
Ethics declarations
Competing interest
K.S.W. is on the scientific advisory board for and is shareholder of Blackfynn, and is a consultant for Xenon Pharmaceuticals. All other authors declare no competing interests.
Additional information
Peer review information
Nature Reviews Neurology thanks I. Ali, R. Surges and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Related links
EpiBioS4Rx: https://epibios.loni.usc.edu
EpimiRNA: https://www.epimirna.eu
EPISTOP: http://epistop.eu
EPITARGET: https://www.epitarget.eu
Supplementary Information
Glossary
- Receiver operating characteristic (ROC) analysis
-
A standard method to determine the sensitivity and specificity of a proposed biomarker.
- Autoradiography
-
A technique in which an image is produced on an X-ray film or nuclear emulsion by the pattern of decay emissions from the distribution of a radioactive substance in a cellular or histological preparation.
- Sleep spindles
-
Trains of distinct waves with frequency at 11–16 Hz detectable on the EEG during sleep.
- Negative predictive value
-
The probability that a patient does not have the disease when the biomarker is negative.
- Positive predictive value
-
The probability that a patient has the disease when the biomarker is positive.
Rights and permissions
About this article
Cite this article
Simonato, M., Agoston, D.V., Brooks-Kayal, A. et al. Identification of clinically relevant biomarkers of epileptogenesis — a strategic roadmap. Nat Rev Neurol 17, 231–242 (2021). https://doi.org/10.1038/s41582-021-00461-4
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-021-00461-4
This article is cited by
-
Understanding the multidimensional neurodevelopmental outcomes in children after congenital Zika virus exposure
Pediatric Research (2024)
-
The Neurovascular Unit Dysfunction in the Molecular Mechanisms of Epileptogenesis and Targeted Therapy
Neuroscience Bulletin (2024)
-
Clinical Correlation of Altered Molecular Signatures in Epileptic Human Hippocampus and Amygdala
Molecular Neurobiology (2024)
-
Neuroinflammatory mediators in acquired epilepsy: an update
Inflammation Research (2023)
-
Malondialdehyde and superoxide dismutase levels in patients with epilepsy: a case–control study
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery (2022)